MREM Press Releases
LintonPharm Announces First Patient Dosed in Phase 1 Clinical Trial of Catumaxomab for Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin
GUANGZHOU, China, Dec 2 (Bernama-BUSINESS WIRE) — LintonPharm Co., Ltd., a China-based clinical stage biopharmaceutical company focused on the development of T cell engaging bispecific antibodies for cancer immunotherapy, today announced that the first patient has been dosed in the Company’s Phase 1/2 clinical trial program for catumaxomab (clinicaltrials.gov: NCT04799847), a monoclonal
Holla Helps Celebrities Go Digital
KUALA LUMPUR, Malaysia, Dec 2 (Bernama-PRNewswire) — Malaysia’s No.1 celebrity engagement platform, hosted its inaugural industry event entitled “How Celebrities Go Digital.” “It is our aim to be the go-to platform for celebrities who want to embrace digital solutions to build meaningful engagements with their fans,” said Jonathan Seevaratnam, Executive
DoctorOnCall Partners Up With Qualitas Group to Bolster Booster Vaccination Drive
KUALA LUMPUR, Malaysia, Dec 2 (Bernama-PRNewswire) — DoctorOnCall, Malaysia’s first and largest digital health platform today announced its partnership with Qualitas Medical Group to form a collaborative alliance to extend COVID-19 vaccination to the population who are yet to receive it, including foreign nationals and adolescents over the age of 12. The initiative
Development continues on Real Realm (Rise Studio)! Post IDO Updates and Upcoming Gate.io Listing
SINGAPORE, Dec 2 (Bernama-GLOBE NEWSWIRE) — Real Realm (Rise Studio) has successfully completed its IDO on Kardiachain and BSC station. There was a huge demand once the sale has started and shortly after a while all the Real Tokens were sold. Amazingly all-time high price was 72x higher than IDO price and the current price is
Square, Inc. Changes Name to Block
SAN FRANCISCO, Dec 2 (Bernama-BUSINESS WIRE) — Square, Inc. (NYSE: SQ) announced today that it is changing its name to Block. Block will be the name for the company as a corporate entity. The Square name has become synonymous with the company’s Seller business, which provides an integrated ecosystem of
Sophi.io Wins at WAN-IFRA Digital Media Awards Worldwide 2021
Sophi Dynamic Paywall wins global award for Best Paid Media Strategy TORONTO, Dec 2 (Bernama-GLOBE NEWSWIRE) — Sophi.io, The Globe and Mail’s artificial intelligence-based automation, optimization and prediction engine, won WAN-IFRA’s 2021 Digital Media Awards Worldwide award in the Best Paid Media Strategy category for Sophi Dynamic Paywall, its real-time, personalized paywall
OneStream Expands Presence in Asia-Pacific with Opening of Singapore Office
BIRMINGHAM, Mich., Dec 2 (Bernama-BUSINESS WIRE) — OneStream, a leader in corporate performance management (CPM) solutions for the world’s leading enterprises, today announced its further expansion across Asia-Pacific with the opening of a Singapore office. OneStream’s new Singapore office will be the third office for the organisation in the APAC
An Opportunity to Use Various Korean APIs, APPETIZER HACKATHON to Be Held for Southeast Asian Region
SEOUL, South Korea, Dec 2 (Bernama-BUSINESS WIRE) — Hosted by Naver Cloud and organized by the Korea Software Industry Association, APPETIZER HACKATHON will accept applications for participation from December 6th (Mon.) 9 am to December 23rd (Thurs.) 3 pm (Korean Standard Time). Held for the first time this year, APPETIZER
Luxury Portfolio International Releases State of Luxury Real Estate Report 2022
Number of Luxury Real Estate Sellers Increases Globally; Some Buyers Expressing FOMO (Strong Fear of Missing Out); Sustainability ‘Critically Important’ Among Affluent Buyers Worldwide Latest Report Comprises Data from Top 1-5% Bracket Surveyed Across 20 Countries, Representing an Affluent Population of Almost 32 Million Households NEW YORK, Dec 2 (Bernama-GLOBE NEWSWIRE)
4TEEN4 Pharmaceuticals Selects AGC Biologics to Manufacture Procizumab
Seattle, Dec 2 (Bernama-GLOBE NEWSWIRE) — AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new partnership with 4TEEN4 Pharmaceuticals GmbH (“4TEEN4”) to manufacture and commercialize Procizumab. The first-in-class monoclonal antibody Procizumab offers a new approach for the treatment of life-threatening diseases related to